Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash from Financing Activities (2017 - 2025)

Sutro Biopharma's Cash from Financing Activities history spans 9 years, with the latest figure at $102000.0 for Q3 2025.

  • For Q3 2025, Cash from Financing Activities fell 89.97% year-over-year to $102000.0; the TTM value through Sep 2025 reached $84000.0, down 99.91%, while the annual FY2024 figure was $94.1 million, 31.62% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was $102000.0 at Sutro Biopharma, up from -$60000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $137.7 million in Q2 2023 and bottomed at -$5.7 million in Q3 2023.
  • The 5-year median for Cash from Financing Activities is $760000.0 (2022), against an average of $14.9 million.
  • The largest annual shift saw Cash from Financing Activities soared 14164.1% in 2022 before it tumbled 139.15% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $506000.0 in 2021, then soared by 2315.22% to $12.2 million in 2022, then crashed by 125.57% to -$3.1 million in 2023, then surged by 99.23% to -$24000.0 in 2024, then soared by 525.0% to $102000.0 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Cash from Financing Activities are $102000.0 (Q3 2025), -$60000.0 (Q2 2025), and $66000.0 (Q1 2025).